Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006479757> ?p ?o ?g. }
- W2006479757 endingPage "1071" @default.
- W2006479757 startingPage "1062" @default.
- W2006479757 abstract "Background: Reports on the natural history of herpes zoster ophthalmicus stress its high morbidity related to vicious scars on eyelids, ocular complications, and postherpetic neuralgia. Early treatment with oral acyclovir is effective, but the optimal duration of treatment has not been defined. Methods: The authors performed a bicentric, prospective, randomized, doublemasked study of 86 patients with acute herpes zoster ophthalmicus, within 72 hours of skin eruption, who received oral acyclovir (800 mg 5 times daily), either for 7 days (plus 7 days oral placebo) or for 14 days. All patients concomitantly received ophthalmic 3% acyclovir ointment; follow-up was at least 6 months. Results: Statistical analyses of subjective symptoms, skin lesions, and ocular complications showed no significant differences between the groups, suggesting that a 7-day course of treatment was sufficient. Drug tolerance was good. Pooled data from both groups corroborated earlier reports that prompt treatment with oral acyclovir reduces the severity of the skin eruption, the incidence and severity of late ocular manifestations, and the intensity of postherpetic neuralgia. At 6 months, late ocular inflammatory complications were seen in 29.1 % of our 86 patients, versus 50% to 71 % of untreated patients described by others. Only 13% of our patients experienced postherpetic neuralgia, which in no case required the use of analgesics. Conclusion: The authors believe it is not useful to prolong treatment with 800 mg of oral acyclovir 5 times daily for more than 7 days in herpes zoster ophthalmicus. This study confirms the efficacy of oral acyclovir not only against skin lesions and ocular complications, but also against postherpetic neuralgia in herpes zoster ophthalmicus. Background: Reports on the natural history of herpes zoster ophthalmicus stress its high morbidity related to vicious scars on eyelids, ocular complications, and postherpetic neuralgia. Early treatment with oral acyclovir is effective, but the optimal duration of treatment has not been defined. Methods: The authors performed a bicentric, prospective, randomized, doublemasked study of 86 patients with acute herpes zoster ophthalmicus, within 72 hours of skin eruption, who received oral acyclovir (800 mg 5 times daily), either for 7 days (plus 7 days oral placebo) or for 14 days. All patients concomitantly received ophthalmic 3% acyclovir ointment; follow-up was at least 6 months. Results: Statistical analyses of subjective symptoms, skin lesions, and ocular complications showed no significant differences between the groups, suggesting that a 7-day course of treatment was sufficient. Drug tolerance was good. Pooled data from both groups corroborated earlier reports that prompt treatment with oral acyclovir reduces the severity of the skin eruption, the incidence and severity of late ocular manifestations, and the intensity of postherpetic neuralgia. At 6 months, late ocular inflammatory complications were seen in 29.1 % of our 86 patients, versus 50% to 71 % of untreated patients described by others. Only 13% of our patients experienced postherpetic neuralgia, which in no case required the use of analgesics. Conclusion: The authors believe it is not useful to prolong treatment with 800 mg of oral acyclovir 5 times daily for more than 7 days in herpes zoster ophthalmicus. This study confirms the efficacy of oral acyclovir not only against skin lesions and ocular complications, but also against postherpetic neuralgia in herpes zoster ophthalmicus." @default.
- W2006479757 created "2016-06-24" @default.
- W2006479757 creator A5000294188 @default.
- W2006479757 creator A5021840313 @default.
- W2006479757 creator A5060219887 @default.
- W2006479757 creator A5063314514 @default.
- W2006479757 creator A5069487066 @default.
- W2006479757 creator A5088234683 @default.
- W2006479757 creator A5089508935 @default.
- W2006479757 date "1992-07-01" @default.
- W2006479757 modified "2023-09-26" @default.
- W2006479757 title "Oral Acyclovir for Herpes Zoster Ophthalmicus" @default.
- W2006479757 cites W1974264133 @default.
- W2006479757 cites W1994111485 @default.
- W2006479757 cites W1999011811 @default.
- W2006479757 cites W2008847459 @default.
- W2006479757 cites W2010659020 @default.
- W2006479757 cites W2019343293 @default.
- W2006479757 cites W2022588543 @default.
- W2006479757 cites W2038781634 @default.
- W2006479757 cites W2039208148 @default.
- W2006479757 cites W2039582424 @default.
- W2006479757 cites W2049734705 @default.
- W2006479757 cites W2051268926 @default.
- W2006479757 cites W2056077512 @default.
- W2006479757 cites W2059873946 @default.
- W2006479757 cites W2061634627 @default.
- W2006479757 cites W2061882782 @default.
- W2006479757 cites W2065217024 @default.
- W2006479757 cites W2065266958 @default.
- W2006479757 cites W2068980929 @default.
- W2006479757 cites W2069423697 @default.
- W2006479757 cites W2070152840 @default.
- W2006479757 cites W2070999333 @default.
- W2006479757 cites W2071023462 @default.
- W2006479757 cites W2079930262 @default.
- W2006479757 cites W2080151474 @default.
- W2006479757 cites W2086295162 @default.
- W2006479757 cites W2094400967 @default.
- W2006479757 cites W2099713623 @default.
- W2006479757 cites W2121369075 @default.
- W2006479757 cites W2127673822 @default.
- W2006479757 cites W2129987908 @default.
- W2006479757 cites W2148286529 @default.
- W2006479757 cites W2150122056 @default.
- W2006479757 cites W2158441425 @default.
- W2006479757 cites W2167298917 @default.
- W2006479757 cites W2328403085 @default.
- W2006479757 cites W2329195529 @default.
- W2006479757 cites W2338795352 @default.
- W2006479757 cites W4249605336 @default.
- W2006479757 cites W4361773804 @default.
- W2006479757 doi "https://doi.org/10.1016/s0161-6420(92)31849-4" @default.
- W2006479757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1495785" @default.
- W2006479757 hasPublicationYear "1992" @default.
- W2006479757 type Work @default.
- W2006479757 sameAs 2006479757 @default.
- W2006479757 citedByCount "73" @default.
- W2006479757 countsByYear W20064797572012 @default.
- W2006479757 countsByYear W20064797572014 @default.
- W2006479757 countsByYear W20064797572015 @default.
- W2006479757 countsByYear W20064797572016 @default.
- W2006479757 countsByYear W20064797572017 @default.
- W2006479757 countsByYear W20064797572018 @default.
- W2006479757 countsByYear W20064797572019 @default.
- W2006479757 countsByYear W20064797572021 @default.
- W2006479757 countsByYear W20064797572022 @default.
- W2006479757 crossrefType "journal-article" @default.
- W2006479757 hasAuthorship W2006479757A5000294188 @default.
- W2006479757 hasAuthorship W2006479757A5021840313 @default.
- W2006479757 hasAuthorship W2006479757A5060219887 @default.
- W2006479757 hasAuthorship W2006479757A5063314514 @default.
- W2006479757 hasAuthorship W2006479757A5069487066 @default.
- W2006479757 hasAuthorship W2006479757A5088234683 @default.
- W2006479757 hasAuthorship W2006479757A5089508935 @default.
- W2006479757 hasConcept C120665830 @default.
- W2006479757 hasConcept C121332964 @default.
- W2006479757 hasConcept C141071460 @default.
- W2006479757 hasConcept C142724271 @default.
- W2006479757 hasConcept C159047783 @default.
- W2006479757 hasConcept C16005928 @default.
- W2006479757 hasConcept C188816634 @default.
- W2006479757 hasConcept C204787440 @default.
- W2006479757 hasConcept C2522874641 @default.
- W2006479757 hasConcept C27081682 @default.
- W2006479757 hasConcept C2776159415 @default.
- W2006479757 hasConcept C2776409557 @default.
- W2006479757 hasConcept C2777107010 @default.
- W2006479757 hasConcept C2778866549 @default.
- W2006479757 hasConcept C2779450786 @default.
- W2006479757 hasConcept C2780016216 @default.
- W2006479757 hasConcept C2780727368 @default.
- W2006479757 hasConcept C2909956880 @default.
- W2006479757 hasConcept C42219234 @default.
- W2006479757 hasConcept C61511704 @default.
- W2006479757 hasConcept C71924100 @default.
- W2006479757 hasConceptScore W2006479757C120665830 @default.
- W2006479757 hasConceptScore W2006479757C121332964 @default.